

Special Issue

Cellular Mechanisms of Rheumatoid Arthritis

Message from the Guest Editor

Rheumatoid arthritis (RA) is a complex autoimmune disease that mainly affects peripheral joints, causing the destruction of joint structure and, ultimately, joint deformity and disability. Multiple cell types play a key role in RA, including immune cells (monocytes/macrophages, B cells, and T cells); fibroblast-like synoviocytes (FLS), which are the joint stromal cells; endothelial cells; and osteoclasts. Research performed during recent decades has improved knowledge of the cellular mechanisms involved in the pathogenesis of RA. However, there are some aspects that have not been fully elucidated, such as the interactions between different cell types, the effect of current therapies at molecular and cellular level, as well as the identification of novel targets that can modulate the functional role of these cell types. This Special Issue will include basic and translational original articles and reviews focused on cellular mechanisms involved in the pathogenesis of RA and the effect of current and novel treatments on these mechanisms, which will allow a better understanding of the pathogenesis of RA.

Guest Editor

Dr. Samuel García Pérez

Rheumatology & Immune-Mediated Diseases (IRIDIS) group, Galicia Sur Health Research Institute (IIS Galicia Sur), Vigo, Spain

Deadline for manuscript submissions

closed (31 August 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/111337

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).